AstraZeneca PLC Identified as Strongest Growth Candidate Among Large European Pharma
AZN Astrazeneca plc
$174.35 -0.60%
View chart & analysis → - 1Citi stated that AstraZeneca PLC is the strongest candidate among large European pharma companies, with 22.8% fair value upside and a 7.3% LTM revenue growth rate.
- 2AstraZeneca PLC's unadjusted peak revenue potential of over $30 billion based on late-stage clinical trials was confirmed.
- 3Sanofi SA offers a 4.9% dividend yield, 11.0% revenue growth, and 47.3% fair value upside.
So what's the key point?
AstraZeneca PLC has been named the top growth candidate among large European pharmaceutical companies. The company has confirmed a potential for future revenue of over $30 billion.
Source Investing.com · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.